Teva Pharmaceutical Industries Ltd.

Major Shareholding Notification • Mar 6, 2024

FORM 4 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b). Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

(Print or Type Responses)

OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response... 0.5

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person Daniell Richard	2. Issuer Name and Ticker or Trading Symbol Teva Pharmaceutical Industries Limited TEVA	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner
(Last) (First) (Middle) C/O Teva Pharmaceutical Industries Ltd. 124 Dvora HaNevi'a St.,	3. Date of Earliest Transaction (Month/Day/Year) 03/03/2024	X Officer (give title below) Other (specify below) Exec. VP, European Commercial
(Street) Tel Aviv, L3 6944020	4. If Amendment, Date Original Filed (Month/Day/Year)	6. Individual or Joint/Group Filing (Check Applicable Line) X - Form filed by One Reporting Person Form filed by More than One Reporting Person
(City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

l .Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year) any	2A. Deemed Execution Date, if (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	Ownership of Indirect Form: Direct (D) Ownership	7. Nature Beneficial
			Code		Amount	(A) Or (D)	Price		or Indirect (Instr. 4) (1) (Instr. 4)
'Ordinary Shares (1)	03/03/2024		M		62,250	A	(2)	132,020	D
'Ordinary Shares (1)	03/04/2024		ડુ(3)		62,250	D	13.3373	69,770	D

				(4)
Ordinary Shares (1)	03/04/2024	M	33,512 A	(2)	103,282	D
Ordinary Shares (1)	03/04/2024			g(3) 33,512 D 13.3373 (4)	69,770	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned ( e.g. . nuts, calls, warrants, ontions, convertible securities)

	6.5, , pulsy Callsy Harramesy options, Course and SCCarreles)
1. Title of	2	3. Transaction	3A. Deemed	4.		5. Number of		6. Date Exercisable		7. Title and Amount			8. Price of 9. Number of	10.	11. Nature
Derivative	Conversion Date		Execution Date, if Transaction Derivative					and Expiration Date		of Underlying			Derivative Derivative	Ownership of Indirect
Security	or Exercise	(Month/Day/Year) any		Code		Securities		(Month/Day/Year)		Securities		Security	Securities	Form of	Beneficial
(Instr. 3)	Price of		(Month/Day/Year) (Instr. 8)			Acquired (A) or				(Instr. 3 and 4)		(Instr. 5)	Beneficially	Derivative	Ownership
	Derivative					Disposed of (D)							Owned	Security:	(Instr. 4)
	Security					(Instr. 3, 4, and 5)							Following	Direct (D)
										Amount or Title Number		Reported	or Indirect
													Transaction(s)	(1)
								Date	Expiration				(Instr. 4)	(Instr. 4)
								Exercisable	Date
											of
				Code		(A)	(D)				Shares
Restricted										Ordinary
Share	(2)	03/03/2024		M			62,250	(2)	(2)	Shares	62,250	\$ 0	186,753	D
Units										(1)
Restricted										Ordinary
Share				M				(6)	(6)					D
	(2)	03/04/2024					33,512			Shares	33,512	\$ 0	67,024
Units										(1)
Restricted										Ordinary
								(7)	(7)
Share	(2)	03/04/2024		A		81,845				Shares	81,845	\$ 0	81,845	D
Units										(1)

Explanation of Responses:

• 1. The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
• 1. Each restricted share unit represents a continent, one ordinary share or at the option of the Human Recources and Compensation Committee, the cast value of one ordinary share.
• 1. The transaction reported in this Form 4 was effected pursuant to a Rule 105-1 trading plan adopted by the reporting person on November 13, 2023.
• 1. The price reported in Column 4 is a weighted arease were sold in multiple transactions at prices ranging from \$1.2.5 to \$1.445, including resor undertakes to provide, upon request by the issuer, or any security holder of the issue, full information rearthing the number of shares solo at each sprare price.
• 1. Restricted share units were granted on March 3, 2024, March 3, 2024, March 3, 2024, March 3, 2026, and 62,253 vesing on March 3, 2027.
• 1. Restricted share units were granted on March 4, 2022, with 3,512 vested on March 4, 2024, and 3,512 vesting on each of March 4, 2026.
• 1. Restricted share units were granted on March 4, 2024, vising on each of Mach 4, 2025, March 4, 2027, and 20,462 vesing on March 4, 2028.

Signatures

/s/ Dov Bergwerk as attorney-in-fact for Richard Daniell 03/05/2024

Date

** Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly.

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information in this form are not required to respond unless the form displays a currently valid OMB Number.